Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 17.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 509722 ISIN: SE0000722365 Ticker-Symbol: OMAX 
Tradegate
10.07.19
16:44 Uhr
0,630 Euro
-0,106
-14,40 %
Branche
Pharma
Aktienmarkt
General Standard
1-Jahres-Chart
OASMIA PHARMACEUTICAL AB Chart 1 Jahr
5-Tage-Chart
OASMIA PHARMACEUTICAL AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,613
0,668
10.07.

Aktuelle News zur OASMIA PHARMACEUTICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Börsennews zur OASMIA PHARMACEUTICAL Aktie und weiteren Hot Stocks erhalten
MoOasmia Pharmaceutical AB: The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million312The Board of Directors in Oasmia Pharmaceutical AB ("Oasmia" or the "Company") today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting...
► Artikel lesen
MoNotice of extraordinary general meeting in Oasmia Pharmaceutical AB262The shareholders of Oasmia Pharmaceutical AB (the "Company") are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan...
► Artikel lesen
27.09.Nasdaq Stockholm AB: Observationsnoteringen för Oasmia Pharmaceutical AB tas bort / The observation status for Oasmia Pharmaceutical AB is removed (143/19)140Den 16 januari 2019 observationsnoterades aktierna i Oasmia Pharmaceutical AB ("Oasmia") med hänvisning till att ägare till minst en tiondel av samtliga aktier i bolaget begärt att en extra bolagsstämma...
► Artikel lesen
26.09.Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019268This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its...
► Artikel lesen
26.09.Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 - July 31, 2019226EVENTS IN FIRST QUARTER Oasmia presented results from two clinical studies of Docecal in patients with metastatic breast cancerThe Board of Directors appointed a special examiner to give all shareholders...
► Artikel lesen
25.09.OASMIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm174New York, New York--(Newsfile Corp. - September 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia" or the...
► Artikel lesen
24.09.OASMIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm227New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB ("Oasmia") or the "Company")...
► Artikel lesen
20.09.OASMIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm192New York, New York--(Newsfile Corp. - September 20, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia" or the...
► Artikel lesen
18.09.Oasmia Pharmaceutical AB: Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte271In connection with Oasmia's year-end report in June 2019, the company's Board of Directors made a decision to engage a special examiner, audit firm Deloitte (Svante Forsberg responsible investigator)...
► Artikel lesen
18.09.Oasmia Pharmaceutical AB: Oasmia presents Q1 report through audiocast on September 26241Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company's Q1 report for the financial year 2019/2020. The presentation of the Q1 report...
► Artikel lesen
15.09.The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019384Oasmia's Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019. The Nomination Committee proposes...
► Artikel lesen
05.09.Oasmia Pharmaceutical AB: Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability169Oasmia Pharmaceutical AB's annual report for the fiscal year 2018/2019 is now available on the company's website www.oasmia.com. Compared to the year-end report, which was published on June 28, the...
► Artikel lesen
04.09.Oasmia Pharmaceutical AB: Oasmia completes its management team287Oasmia has further strengthen its management team with the recruitment of two General Managers to accelerate commercialization of Oasmia. Neil Yman is appointed General Manager for Europe & Russia and...
► Artikel lesen
04.09.LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Oasmia Pharmaceutical AB to Contact the Firm150New York, New York--(Newsfile Corp. - September 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia") or the...
► Artikel lesen
28.08.Notice of Annual General Meeting in Oasmia Pharmaceutical AB178This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. The shareholders of Oasmia Pharmaceutical AB are hereby given...
► Artikel lesen
27.08.Oasmia Pharmaceutical AB: Oasmia updates regarding MGC disputes156During the preceding weekend, the initially yearly promissory note loan which Nexttobe provided to Oasmia back in 2015 has finally fallen due after several extensions. Also, it was the intended refinancing...
► Artikel lesen
23.08.Oasmia Pharmaceutical AB: Oasmia ADSs delisted from NASDAQ in the US248Oasmia Pharmaceutical AB has previously communicated that the company intends to delist its American Depositary Shares ("ADS") from the Nasdaq Capital Market ("NASDAQ") in the US. The delisting...
► Artikel lesen
21.08.Oasmia Pharmaceutical AB - 6-K, Report of foreign issuer-
20.08.Oasmia Pharmaceutical AB: Nomination committee in Oasmia for the 2019 AGM193In accordance with the decision at the Annual General Meeting of Oasmia Pharmaceutical AB on September 25, 2018, the two largest shareholders in terms of voting rights who have chosen to participate...
► Artikel lesen
15.08.LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm203New York, New York--(Newsfile Corp. - August 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia") (or the...
► Artikel lesen
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1